ZA201202618B - Combinations of a p13k inhibitor and a mek inhibitor - Google Patents

Combinations of a p13k inhibitor and a mek inhibitor

Info

Publication number
ZA201202618B
ZA201202618B ZA2012/02618A ZA201202618A ZA201202618B ZA 201202618 B ZA201202618 B ZA 201202618B ZA 2012/02618 A ZA2012/02618 A ZA 2012/02618A ZA 201202618 A ZA201202618 A ZA 201202618A ZA 201202618 B ZA201202618 B ZA 201202618B
Authority
ZA
South Africa
Prior art keywords
inhibitor
combinations
mek
mek inhibitor
Prior art date
Application number
ZA2012/02618A
Other languages
English (en)
Inventor
Marcia Belvin
John Prescott
Iris T Chan
Klaus P Hoeflich
Jeffrey Wallin
Lori Friedman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43072663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201202618(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA201202618B publication Critical patent/ZA201202618B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ZA2012/02618A 2009-10-12 2012-04-11 Combinations of a p13k inhibitor and a mek inhibitor ZA201202618B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25085209P 2009-10-12 2009-10-12
PCT/EP2010/065149 WO2011054620A1 (en) 2009-10-12 2010-10-11 Combinations of a pi3k inhibitor and a mek inhibitor

Publications (1)

Publication Number Publication Date
ZA201202618B true ZA201202618B (en) 2014-10-29

Family

ID=43072663

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/02618A ZA201202618B (en) 2009-10-12 2012-04-11 Combinations of a p13k inhibitor and a mek inhibitor

Country Status (24)

Country Link
US (1) US20110086837A1 (enExample)
EP (1) EP2488178B1 (enExample)
JP (2) JP2013507415A (enExample)
KR (1) KR101489045B1 (enExample)
CN (1) CN102740851B (enExample)
AR (1) AR078588A1 (enExample)
AU (1) AU2010314287A1 (enExample)
BR (1) BR112012008483A2 (enExample)
CA (1) CA2776944A1 (enExample)
CL (1) CL2012000913A1 (enExample)
CO (1) CO6531463A2 (enExample)
CR (1) CR20120173A (enExample)
EC (1) ECSP12011865A (enExample)
ES (1) ES2609767T3 (enExample)
IL (1) IL219105A0 (enExample)
MA (1) MA33974B1 (enExample)
MX (1) MX345155B (enExample)
NZ (1) NZ599939A (enExample)
PE (1) PE20121816A1 (enExample)
PH (1) PH12012500709A1 (enExample)
RU (1) RU2563193C2 (enExample)
TW (1) TWI428336B (enExample)
WO (1) WO2011054620A1 (enExample)
ZA (1) ZA201202618B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2729914A1 (en) 2008-07-11 2010-01-14 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
ES2550032T3 (es) 2009-01-08 2015-11-04 Curis, Inc. Inhibidores de fosfoinosítido 3-quinasa con un resto de unión a cinc
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
ME03523B (me) 2011-04-01 2020-04-20 Curis Inc Inhibitori fosfoinozitid 3 kinaze sa dijelom koji vezuje cink
CA2843595C (en) * 2011-08-01 2022-10-18 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
KR20140072028A (ko) * 2011-08-31 2014-06-12 노파르티스 아게 Pi3k- 및 mek-억제제의 상승작용적 조합물
EP2766011B1 (en) 2011-10-13 2017-09-27 Genentech, Inc. Treatment of pharmacological-induced hypochlorhydria in cancer patients
BR112014009953A2 (pt) * 2011-10-28 2017-12-05 Genentech Inc método de inibição do crescimento de tumores, de tratamento de melanoma, artigo industrializado e uso
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
SG11201406199TA (en) * 2012-04-06 2014-10-30 Sanofi Sa Methods for treating cancer using pi3k inhibitor and mek inhibitor
US9566307B2 (en) 2012-04-19 2017-02-14 Kyushu University, National University Corporation Pharmaceutical composition
NZ702244A (en) 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
JP2015528818A (ja) 2012-08-02 2015-10-01 ジェネンテック， インコーポレイテッド 抗ｅｔｂｒ抗体およびイムノコンジュゲート
AR093227A1 (es) 2012-08-02 2015-05-27 Genentech Inc Inmunoconjugados y anticuerpos contra el receptor de endotelina b (anti-etbr)
CA2928396A1 (en) * 2012-08-17 2014-02-20 F. Hoffmann-La Roche Ag Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
CN105246508A (zh) * 2013-03-14 2016-01-13 基因泰克公司 Mek抑制剂化合物与her3/egfr抑制剂化合物的组合及使用方法
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
ES2945387T3 (es) 2014-02-07 2023-06-30 Verastem Inc Procedimientos y composiciones para tratar el crecimiento celular anormal
SG10202007111TA (en) 2014-07-15 2020-09-29 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
EP3193902A4 (en) * 2014-09-11 2018-03-28 The Regents of The University of California mTORC1 INHIBITORS
WO2020055840A1 (en) 2018-09-11 2020-03-19 Curis Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN110420330B (zh) * 2019-07-19 2020-05-29 南京医科大学 一种pi3k与mth1靶向药组合物的制药用途
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) * 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) * 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) * 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
CH592668A5 (enExample) * 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) * 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
BR9507203A (pt) * 1994-04-01 1997-09-09 Shionogi & Co Derivado de oxima e bactericida que contém o mesmo como ingredientes ativo
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US7498304B2 (en) * 2000-06-16 2009-03-03 Curis, Inc. Angiogenesis-modulating compositions and uses
JP3811775B2 (ja) * 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
JP4617299B2 (ja) * 2003-03-03 2011-01-19 アレイ バイオファーマ、インコーポレイテッド ｐ３８阻害剤及びその使用法
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1674452A4 (en) * 2003-09-19 2007-10-10 Chugai Pharmaceutical Co Ltd NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
CN103524392B (zh) * 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
HRP20100446T1 (hr) 2006-04-26 2010-09-30 F. Hoffmann-La Roche Ag Derivat tieno[3,2-d]pirimidina koristan kao inhibitor pi3k
EP2056829B9 (en) * 2006-08-16 2012-09-26 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
NZ578162A (en) * 2006-12-07 2011-12-22 Genentech Inc Phosphoinositide 3-kinase inhibitor compounds and methods of use
CL2008002687A1 (es) 2007-09-12 2009-01-16 Genentech Inc Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico.
EP2694073B1 (en) * 2011-04-01 2018-08-08 Genentech, Inc. Combinations of akt and mek inhibitors for treating cancer

Also Published As

Publication number Publication date
JP5745678B2 (ja) 2015-07-08
PE20121816A1 (es) 2013-01-02
CA2776944A1 (en) 2011-05-12
EP2488178B1 (en) 2016-11-16
ECSP12011865A (es) 2012-06-29
CN102740851A (zh) 2012-10-17
JP2015038110A (ja) 2015-02-26
AR078588A1 (es) 2011-11-16
AU2010314287A1 (en) 2012-05-03
RU2012118974A (ru) 2013-11-20
TWI428336B (zh) 2014-03-01
CR20120173A (es) 2012-07-04
MA33974B1 (fr) 2013-02-01
TW201118082A (en) 2011-06-01
KR101489045B1 (ko) 2015-02-02
NZ599939A (en) 2014-02-28
EP2488178A1 (en) 2012-08-22
WO2011054620A1 (en) 2011-05-12
MX2012004286A (es) 2012-05-22
RU2563193C2 (ru) 2015-09-20
MX345155B (es) 2017-01-18
CN102740851B (zh) 2013-12-18
BR112012008483A2 (pt) 2019-09-24
PH12012500709A1 (en) 2012-10-29
HK1175125A1 (en) 2013-06-28
JP2013507415A (ja) 2013-03-04
CL2012000913A1 (es) 2012-09-14
AU2010314287A2 (en) 2012-07-12
CO6531463A2 (es) 2012-09-28
KR20120064132A (ko) 2012-06-18
US20110086837A1 (en) 2011-04-14
ES2609767T3 (es) 2017-04-24
IL219105A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
ZA201202618B (en) Combinations of a p13k inhibitor and a mek inhibitor
HUE067723T2 (hu) MEK-inhibitort és B-Raf-inhibitort tartalmazó kombináció
IL217558A0 (en) Benzoxazepin p13k inhibitor compounds and methods of use
SG10201401169QA (en) Dihydroorotate dehydrogenase inhibitors
IL199727A0 (en) Inhibitors of mek
EP2606031A4 (en) AUTOTAXINE INHIBITORS AND APPLICATIONS THEREOF
ZA201201365B (en) Plant pathogen inhibitor combinations and methods of use
IL214226A (en) Inhibitors of beta-secretase and various related aspects thereof
HUE060473T2 (hu) Aldóz-reduktáz inhibitorok és felhasználásuk
ZA201306973B (en) Combination of a phosphatidylinositol-3kinase(p13k) inhibitor and a mtor inhibitor
IL226005A0 (en) Inhibitors of cell death and uses thereof
GB0908280D0 (en) Trackbed liner and related methods
GB0917927D0 (en) Ido inhibitors and therapeutic uses thereof
GB201009704D0 (en) P13K inhibitors and uses thereof
IL214333A0 (en) Carbamoylphosphonates as inhibitors and uses thereof
GB0911102D0 (en) Enzyme inhibitor
GB0904936D0 (en) Enzyme inhibitor
GB0912985D0 (en) A sleave head piece and a method of manufacture thereof
GB0809975D0 (en) A multi-optic rule and method of use
IL207069A (en) An elongated table and a method for extending it
GB0903533D0 (en) A construction element and method of construction
GB0903474D0 (en) A construction element and method of construction
IL216594A0 (en) Proteasome inhibitors and uses thereof
ZA201004712B (en) A pit and a method of making a pit liner
GB0908609D0 (en) New use of isoQC inhibitors